Exploring the Technology
of Tomorrow

Medical Progress through High Technology

Shaping the future of healthcare through innovation

Empowering life sciences and deep tech innovation through a unique blend of venture building and strategic capital investment.

Capstan Medical is commitment to transforming the treatment of structural heart disease. By merging surgical robotics with catheter-based technology and next generation implants, Capstan Medical pioneered a patient-optimized approach to repair and replace heart valves. Biofund is a seed stage investor.

Dystrogen Therapeutics is a clinical-stage chimeric cell therapy company focusing on rare diseases. The company is currently testing in humans the Dystrophic Expressing Chimeric (DEC) cell therapy for Duchenne Muscular Dystrophy – a terminal illness that affects young boys and lead the gradually worsening dysfunction of the muscular system.


Dystrogen Gene Therapies is a life sciences company focused on the development of therapies for rare genetic neurodegenerative disorders. Our currently most advanced therapeutic candidate is for Huntington’s Disease (HD) and has produced a series of highly promising pre-clinical data.


Holo Surgical Inc. is a company focused on computer-assisted surgery, that has developed an FDA-certified, Artificial Intelligence and Augmented Reality based surgery guidance system, that helps doctors (and later robots) perform medical procedures more precisely, safer, and faster.

Labtronic is a robotic company developing autonomous laboratory solutions

Medicalgorithmics (MDG) is a medical technology company focusing on cardiology. The company has a number of AI based, FDA cleared software algorithms and medical devices. As of 2022, the company performed 170,000 annual cardiac tests worldwide. Biofund is the major owner of MDG, which is publicly traded.

The BISHEP intracanal system is Robotron’s robotic-assisted platform for endoscopic spinal decompression, designed to be a safe and effective tissue-preserving alternative to spinal laminectomy.

Inteneural Networks has developed cutting-edge, AI- and Machine Learning based medical applications that help in brain diagnosis and produce in minutes what would take experienced neuroradiologists hours or days of work.  These applications can detect even hard to identify potential problems that are likely to be missed by human doctors.  INN can revolutionize the field of neuroscience and lead to improved patient outcomes.

Kardiolytics has the goal to make advanced, highly accurate diagnostics of the heart – inexpensive and widely available, including the parts of the world that currently have limited access to advanced medical diagnostics.  The Kardiolytics technology uses Artificial Intelligence to derive from inexpensive and widely available CT scans of the heart – crucial diagnostic information about narrowing of blood vessels, that normally can be obtained only by applying complex, expensive, and highly invasive procedures that involve inserting probes into the heart.

About us

SV was established in 2015 by Dr. Kris Siemionow, MD, PhD a surgeon and the founder of multiple commercial stage medical companies.

About us

Dr. Kris B. Siemionow, M.D., Ph.D. is the founder and principal of SV, a life-sciences and technology focused venture building and crossover fund investing in the most breakthrough ideas that will revolutionize healthcare and tech.


Prior to starting SV, Dr. Siemionow was a board-certified spine surgeon and Tenured Associate Professor of Orthopaedics and Neurosurgery at the University of Illinois in Chicago.


As an entrepreneur Dr. Siemionow focuses on applying machine learning technologies to life-sciences, biotech, and medical devices.


Dr. Siemionow is currently on the board of Medicalgorithmics, a commercial stage cardiac technology company.

About us

Dr. Siemionow was the founder and CEO of HoloSurgical, a digital surgery company, which performed the first in man surgery with its augmented reality and artificial intelligence system on January 9th, 2019. The Company was acquired in October of 2020.


Dr. Siemionow was the founder of Inteneural Networks Inc, a company developing AI tools for brain MRI analytics. The company was acquired in December of 2021.


Dr. Siemionow is co-founder and director at Dystrogen Therapeutics, a clinical stage cell engineering company, which is developing chimeric cell therapies for musculoskeletal, neurologic, and blood disorders. www.dystrogen.com


Dr Siemionow is co-founder and director at Dystrogen Gene Therapies, which is developing an RNAi based approach for CAG repeat disorders like Huntington’s disease. www.dystrogene.com

About us

Dr. Siemionow has published over 100 scientific articles focusing on digital surgery, artificial intelligence, cell therapy, and neurosurgery. He holds multiple patents for developing devices and technologies used in nerve regeneration, digital surgery, cardiology, spine surgery, cell therapy many of which have been commercialized. His PhD focused on studying the effects of inflammation on the central and peripheral nervous system.


Dr. Siemionow is co-founder of Global Spine Outreach. As part of Global Spine Outreach, Dr. Siemionow performed surgery in several European and Central American cities. Dr. Siemionow also participated in spine surgery missions to Uganda, East Africa, where he treated both children and adults suffering from spinal trauma, scoliosis, tumors, and infection.


Dr. Siemionow completed a residency in Orthopaedic Surgery at the Cleveland Clinic in Cleveland, Ohio and fellowship training in Adult Spine Surgery at Rush University Medical Center and a Pediatric Spine Fellowship at the Shriners Hospital for Children.